Zaloguj Zarejestruj się zadarmo

Panbela Therapeutics organizacji Kapitalizacja rynkowa

Jaka jest wartość Kapitalizacja rynkowa organizacji Panbela Therapeutics?

Wartość Kapitalizacja rynkowa organizacji Panbela Therapeutics Inc. to $1.22M

Jaka jest definicja Kapitalizacja rynkowa?



Kapitalizacja rynkowa (Market cap) jest wartością rynkową wyemitowanych akcji spółki giełdowej i jest równa cenie akcji w tym czasie pomnożonej przez liczbę wyemitowanych akcji .

As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.

Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.

The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.

Kapitalizacja rynkowa firm w Health Care sektor na NASDAQ w porównaniu do Panbela Therapeutics

Czym się zajmuję organizacja Panbela Therapeutics?

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Firmy z kapitalizacja rynkowa podobne do Panbela Therapeutics